Gilead Sciences Newswire

Comprehensive Real-Time News Feed for Gilead Sciences.

Results 1 - 20 of 1,287 in Gilead Sciences

  1. Exclusive: Biogen prices hemophilia drug on par with older therapiesRead the original story w/Photo

    1 hr ago | Reuters

    ... scrutiny as state governments and health insurers balk over the $84,000 cost of a new hepatitis C drug from Gilead Sciences Inc. Treating two-thirds of the estimated 3.2 million U.S. hepatitis C patients with the drug could top $200 billion, ...

    Comment?

  2. UnitedHealth: New hepatitis C drug costs far more than forecastRead the original story

    6 hrs ago | Lincoln Daily News

    U nitedHealth Group Inc, the largest U.S. health insurer, said it spent more than $100 million to cover a pricey new hepatitis C drug from Gilead Sciences Inc in its first three months on the market, an amount that was "multiple" times what it had expected.

    Comment?

  3. Wall Street week aheadRead the original story w/Photo

    8 hrs ago | Today.Az

    ... 6.1 percent on the year. Along with Facebook Inc (FB.O) and Netflix Inc (NFLX.O), momentum names such as Gilead Sciences Inc (GILD.O), Biogen Idec Inc (BIIB.O) and Illumina Inc (ILMN.O) are set to post results. Investors are gearing up for wild ...

    Comment?

  4. Why People Love Working For Big Pharmas Like Biogen Idec, Inc....Read the original story

    8 hrs ago | BioSpace

    Companies like Celgene, Biogen Idec, and Gilead Sciences all took top spots on our list of the Best Employers in America.

    Comment?

  5. UnitedHealth's first-quarter profit tumblesRead the original story

    9 hrs ago | The Reporter

    ... new treatment Sovaldi, added $100 million to medical costs in the quarter. Regulators approved Sovaldi, from Gilead Sciences Inc., last December. The drug is seen as a breakthrough treatment, but its $1,000-a-pill price tag has drawn some skepticism ...

    Comment?

  6. UnitedHealth already seeing effects of Gilead's pricey hepatitis C drugRead the original story w/Photo

    21 hrs ago | MarketWatch

    ... of several wonder drugs that are expected to profoundly affect treatment of the disease, Sovaldi is made by Gilead Sciences Inc. Sovaldi is considered the most promising of a class of hepatitis C drugs, and was found in tests to have a cure rate ...

    Comment?

  7. Why Everyone Wants To Work In BiotechRead the original story

    22 hrs ago | SFGate

    Companies like Celgene, Biogen Idec, and Gilead Sciences all took top spots on our list of the Best Employers in America .

    Comment?

  8. If This Biotech Drops Much Further I'm Going to Buy ItRead the original story w/Photo

    Yesterday | The Motley Fool

    ... that if it drops much further I'm going to buy it. Three reasons Gilead shares are down Let me be clear, Gilead Sciences shareholders have already had quite the run higher. Shares could have been purchased for less than $20 per share ...

    Comment?

  9. UnitedHealth's 1st-quarter profit tumbles 8 per cent, insurer cites overhaul costsRead the original story

    Yesterday | Coast Reporter

    ... new treatment Sovaldi, added $100 million to medical costs in the quarter. Regulators approved Sovaldi, from Gilead Sciences Inc., last December. The drug is seen as a breakthrough treatment, but its $1,000-a-pill price tag has drawn some skepticism ...

    Comment?

  10. Young Scientists From Around the State Will Compete for Top Honors at ...Read the original story w/Photo

    Wednesday | Sys-Con Media

    The Fair's presenting sponsor is Northrop Grumman Corporation with additional support from Chevron Corporation, Southern California Gas Company, THE MUSES of the California Science Center Foundation, The Ralph M. Parsons Foundation and Gilead Sciences, Inc. , the Director of Business and Advanced Systems Development for Civil Air and Space at ... (more)

    Comment?

  11. Gilead Sciences, Inc. Feeling Sovaldi Pressure From All SidesRead the original story

    Wednesday | The Motley Fool

    One of the sparks that ignited the recent biotech sell-off was the backlash over the cost of Gilead Sciences ' highly effective hepatitis C therapy.

    Comment?

  12. Sovaldi: Who's to Blame for the $1,000 a Day Cure?Read the original story

    Wednesday | Knowledge@Wharton

    When Foster City, Calif.-based Gilead Sciences was developing its hepatitis C treatment, Sovaldi, the medical community was wowed by the 90% cure rate the drug racked up in clinical trials.

    Comment?

  13. Follicular Lymphoma - Pipeline Review, H1 2014 - New Study ReleasedRead the original story

    Wednesday | SBWire

    ... in this Report: Bristol-Myers Squibb Company, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., Merck & Co., Inc., Infinity Pharmaceuticals, Inc., Millennium Pharmaceuticals, Inc., Novartis AG, ImmunoGen, Inc., Genmab A/S, ...

    Comment?

  14. Gilead Sciences, Inc. To Release First Quarter 2014 Financial Results On Tuesday, April 22, 2014Read the original story

    Wednesday | BioSpace

    Gilead Sciences, Inc. announced today that its first quarter 2014 financial results will be released on Tuesday, April 22, at 4:05 p.m. Eastern Time.

    Comment?

  15. U.S. health care usage, spending resume rise in 2013: ReportRead the original story w/Photo

    Tuesday Apr 15 | Business Insurance

    ... with extremely high cure rates and few side effects. The first of those hepatitis drugs, Sovaldi, from Gilead Sciences Inc., has led to intense criticism for its price tag of about $84,000 for a 12-week course of treatment. "It's interesting to see ...

    Comment?

  16. Rheumatoid Arthritis - Pipeline Review, H1 2014: New Research Report...Read the original story

    Wednesday | SBWire

    ... plc, Genentech, Inc., Inovio Pharmaceuticals, Inc., MedImmune, LLC, Isis Pharmaceuticals, Inc., Gilead Sciences, Inc., Biotest AG, Daiichi Sankyo Company, Limited, Merck & Co., Inc., Santen Pharmaceutical Co., Ltd., Ablynx NV, AbGenomics ...

    Comment?

  17. Stock Picks: Three Biotech Big-Caps to Look AtRead the original story w/Photo

    Wednesday | CNN

    ... companies (including two from the industry watchdog's list) and examine why they are worth your penny. Gilead Sciences Inc. (NASDAQ: GILD) is all the rage the past year. J.P. Morgan believes the company will enjoy tremendous earnings again this year ...

    Comment?

  18. Hepatitis C drugs not reaching poorRead the original story w/Photo

    Tuesday Apr 15 | NatureNews

    ... private health insurers and public health-care systems tend to bear the costs of drugs. Sofosbuvir, made by Gilead Sciences in Foster City, California, debuted last December at $1,000 a pill - $84,000 for a 12-week course. And Janssen ...

    Comment?

  19. Wells Fargo & Co. Reiterates "Buy" Rating for Gilead SciencesRead the original story

    Tuesday | AmericanBankingNews.com

    ... of a number of other recent research reports. Analysts at Nomura raised their price target on shares of Gilead Sciences from $120.00 to $121.00 in a research note on Thursday, April 10th. They now have a "buy" rating on the stock. Separately, ...

    Comment?

  20. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story

    Tuesday | Business Wire

    ... does not currently impact bond ratings for the project's owner, the Public Utility District No. 2... )--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2014 financial results will be released on Tuesday, April 22, at 4:05 ...

    Comment?